Table 1 Oncologic outcomes of grade group 2 Prostate Cancer (PCa) patients enrolled in active surveillance (AS) protocols
From: Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
Cohort | Type | Years | Total nr. | IR (GG2) | Median follow-up, yrs (IQR) | TFS | MFS | CSS |
|---|---|---|---|---|---|---|---|---|
Toronto Sunnybrook (Musunuru et al., 2016, Yamamoto et al., 2016) | Prospective | 1995–2013 | 945 | 213 (102) | 7 (4–10) | 15y, IR vs. LR: 47.8% vs. 58.2% | 15y, IR vs. LR: 82.2% vs. 94.6% | 15y, IR vs. LR: 88.5% vs. 96.7% |
Royal Marsden (Selvadurai et al., 2013) | Prospective | 2002–2011 | 471 | 88 (33) | 6 (NR) | 5y: 70% (entire cohort) | Metastases reported in two patients, one of which had Gleason 3 + 4 at diagnosis | 5y: 96% (entire cohort) |
UCSF (Maggi et al., 2020) | Prospective | 1990–2018 | 1450 | 216 (147) | 6 (4–10) | 7y, GG2: 46% | 7y, GG2: 96% | 7y: >99% (entire cohort) |
Multicenter Canary PASS (Weismann Malaret et al., 2022) | Prospective | 2008–2020 | 1728 | NR (154) | 6 (3–9) | 5y, GG2 vs. GG1: 42% vs. 66% | Six pts with GG1 developed metastases, none with GG2. | NR |
MSKCC (Carlsson et al., 2020) | Retrospective | 2000–2017 | 219 | 219 (219) | 3 (2–5) | 5y: 61% | 5y: 100% | 5y: 100% |
UCLH (Stavrinides et al., 2020) | Retrospective | 2004–2017 | 672 | NR (148) | 5 (3–7) | 5y: MRI visible GG2 34%; non-visible GG2 63% | Lower in MRI visible GG2 (p = 0.01) | Lower in MRI visible GG2 (p = 0.001) |